Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
doi: 10.1016/j.pbb.2015.12.007, 8 BlundellJ.FinlaysonG.AxelsenM.FlintA.GibbonsC.KvistT.et al
TRIUMPH-3: Weight management in people with cardiovascular disease Additional TRIUMPH Trials: Type 2 diabetes management Chronic low back pain Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH/NAFLD) Cardiovascular and renal outcomes The TRIUMPH program has enrolled more than 5,800 participants total, making it one of the largest Phase 3 programs for an obesity medication in history
Urgert R, Vliet TV, Zock PL, et al
Our injections are administered by licensed medical professionals using medical-grade ingredients
The 2023 Phase 2 dataset and all 20242025 practice-based frameworks address retatrutide as monotherapy only
Dose titration helps tolerability
